 KNOXVILLE, TN, March 30, 2021 GLOBE NEWSWIRE -- Provectus OTCQB: PVCT today announced that the United States Patent and Trademark Office USPTO has allowed US patent USP application 16678,133, which covers the use of intralesional aka intratumoral PV-10, an injectable formulation of Provectus proprietary small molecule rose bengal disodium RBD, in concomitant combination with two immune checkpoint inhibitors e.g., PV-10 an anti-CTLA-4 agent an anti-PD-L1 agent for the treatment of adult solid tumor cancers such as melanoma, breast cancer, primary and metastatic liver cancers, prostate cancer, and small cell and non-small cell lung cancer. 